Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as a clinical trial, phase iii.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

PREVAIL was an open-label, phase 3 trial comprising a 48-week treatment phase followed by a second 48-week treatment phase.

Patients were followed for 20 weeks after the final infusion (end-of-study visit at week 104).

How the Study Was Run

The researchers set it up as a double-blind, open-label and placebo-controlled study.

Blinding on both sides kept the participants and researchers unaware of who received CGRP (Calcitonin Gene-Related Peptide).

Nothing was hidden in this open-label CGRP (Calcitonin Gene-Related Peptide) study: the participants and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with CGRP (Calcitonin Gene-Related Peptide) could be set against what happens without it.

The timeline in the abstract includes 20 weeks.

What Was Measured

PubMed files the paper under topics including Administration, Intravenous, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Migraine Disorders, Nasopharyngitis, Patient Reported Outcome Measures and Quality of Life.

Author keywords: Chronic migraine, Effectiveness, Eptinezumab, Immunogenicity and Safety.

What This Means in Plain Language

The paper is a double-blind, open-label and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine over 20 weeks.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (BMC neurology), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.